← FDA DRUG APPROVALS

FDA ANDA · ANDA202778

DOXYCYCLINE

Sponsor: STRIDES PHARMA

APPLICATION
ANDA202778
TYPE
ANDA
ORIGINAL APPROVAL
2012-06-08
LATEST ACTION
2026-05-27
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

DOXYCYCLINEDiscontinued
DOXYCYCLINE EQ 150MG BASE · CAPSULE · ORAL

Approval history

2026-05-27Labeling · Supplement 9 · standardAP
2026-05-27Labeling · Supplement 7 · standardAP
2026-05-27Labeling · Supplement 5 · standardAP
2026-05-27Labeling · Supplement 10 · standardAP
2026-05-27Labeling · Supplement 6 · standardAP
2014-11-26Labeling · Supplement 4 · standardAP
2014-06-17Labeling · Supplement 3 · standardAP
2012-06-08UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →